IDH1 and acute myeloid leukemia: Given the identification of multiple new molecular genetic abnormalities in patients with AML, an increasing number of studies have been performed to delineate the mutational frequency and prognostic implications of IDH1/2, TET2, and DNMT3A mutations in AML patients.